Innophos Holdings, Inc. (IPHS) Receives Average Recommendation of “Buy” from Brokerages

Shares of Innophos Holdings, Inc. (NASDAQ:IPHS) have been assigned an average broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. Innophos’ rating score has declined by 100% in the last three months as a result of various analysts’ ratings changes.

Zacks has also given Innophos an industry rank of 38 out of 265 based on the ratings given to its competitors.

A number of research firms have weighed in on IPHS. Zacks Investment Research lowered shares of Innophos from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. BidaskClub lowered shares of Innophos from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. Finally, TheStreet lowered shares of Innophos from a “b-” rating to a “c” rating in a research report on Wednesday, February 21st.

Shares of NASDAQ IPHS traded up $0.09 during midday trading on Thursday, hitting $41.58. 56,986 shares of the company’s stock were exchanged, compared to its average volume of 143,689. The company has a current ratio of 2.64, a quick ratio of 1.36 and a debt-to-equity ratio of 0.93. The company has a market cap of $798.28, a PE ratio of 16.87 and a beta of 0.77. Innophos has a twelve month low of $38.66 and a twelve month high of $51.34.

Innophos (NASDAQ:IPHS) last issued its quarterly earnings data on Wednesday, February 21st. The specialty chemicals company reported $0.52 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.56 by ($0.04). The business had revenue of $193.10 million for the quarter, compared to analyst estimates of $194.25 million. Innophos had a return on equity of 14.02% and a net margin of 3.11%. The business’s quarterly revenue was up 15.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.52 earnings per share. sell-side analysts forecast that Innophos will post 2.7 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Ramsey Quantitative Systems acquired a new position in Innophos in the fourth quarter valued at approximately $134,000. Macquarie Group Ltd. bought a new position in Innophos in the third quarter valued at $193,000. Vident Investment Advisory LLC bought a new position in Innophos in the fourth quarter valued at $201,000. Piedmont Investment Advisors LLC bought a new position in Innophos in the third quarter valued at $209,000. Finally, Alps Advisors Inc. bought a new position in Innophos in the fourth quarter valued at $213,000. 93.37% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://sportsperspectives.com/2018/04/17/innophos-holdings-inc-iphs-receives-average-recommendation-of-buy-from-brokerages.html.

Innophos Company Profile

Innophos Holdings, Inc is an international producer of specialty ingredient solutions that deliver for the food, health, nutrition and industrial markets. The Company’s segments include Food, Health and Nutrition, Industrial Specialties and Other. It offers a range of product categories, such as asphalt, catalyst, fertilizer salts, liquid phosphate, phosphate salt, phosphoric acid, polyphosphoric acid, sodium bicarbonate, and food blends.

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply